Amorphous Solid Dispersion for c-KIT Inhibitor Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for refractory gastrointestinal stromal tumors (GIST) and other disorders associated with c-KIT and PDGFRα mutations lack effective, stable oral formulations with good therapeutic properties.
Innovation Solution
Development of pharmaceutical compositions comprising a compound of Formula (I), a compound of Formula (II), and one or more pharmaceutically acceptable carriers, excipients, or diluents, with specific amounts of anilinic substances to ensure purity and safety for pharmaceutical preparations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for refractory GIST and other disorders associated with c-KIT and PDGFRα mutations are used, then therapeutic effects are limited, but formulation stability and therapeutic properties are insufficient
Solution Approach 1:
The patent changes the physical and chemical parameters of the active ingredient through solid dispersion technology, transforming it from an unstable crystalline form to a stable amorphous state within a polymer matrix. This parameter change dramatically improves both formulation stability and therapeutic effectiveness by enhancing solubility and bioavailability of the c-KIT inhibitor
Solution Approach 2:
The invention creates a composite material system combining the active pharmaceutical ingredient with polymer carriers in a solid dispersion formulation. This composite approach integrates the therapeutic agent with stabilizing excipients to simultaneously achieve formulation stability and improved therapeutic effectiveness for refractory GIST treatment
2Ease of operation
If oral formulations are developed for c-KIT and PDGFRα inhibitors, then therapeutic accessibility is improved, but stability and purity control are challenging
Solution Approach 1:
The patent introduces polymer carriers as intermediary substances that mediate between the active ingredient and the oral administration route. These polymers act as protective intermediaries that maintain drug stability during manufacturing and ensure consistent purity while enabling convenient oral delivery of the c-KIT inhibitor
Solution Approach 2:
The solid dispersion process transforms the physical state and dissolution parameters of the active ingredient, creating a formulation that is both orally convenient and manufacturable with precise purity control. The amorphous state achieved through this parameter change ensures consistent drug content and purity during oral administration
Data Source
AI summary
Provided herein are low impurity compositions comprising a compound represented by Formula (I):which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.